These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27196668)

  • 41. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
    Li G; Lin SS; Yu ZL; Wu XH; Liu JW; Tu GH; Liu QY; Tang YL; Jiang QN; Xu JH; Huang QL; Wu LX
    Biochem Pharmacol; 2022 Dec; 206():115329. PubMed ID: 36309080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF; Matulonis UA
    Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.
    Ray U; Thirusangu P; Jin L; Xiao Y; Pathoulas CL; Staub J; Erskine CL; Dredge K; Hammond E; Block MS; Kaufmann SH; Bakkum-Gamez JN; Shridhar V
    Oncogene; 2023 Sep; 42(37):2725-2736. PubMed ID: 37550562
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
    Davidson D; Wang Y; Aloyz R; Panasci L
    Invest New Drugs; 2013 Apr; 31(2):461-8. PubMed ID: 23054213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reverse the Resistance to PARP Inhibitors.
    Kim Y; Kim A; Sharip A; Sharip A; Jiang J; Yang Q; Xie Y
    Int J Biol Sci; 2017; 13(2):198-208. PubMed ID: 28255272
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB-Triggered SASP in Cancer-Associated Fibroblasts.
    Jin P; Li X; Xia Y; Li H; Li X; Yang ZY; Wang Z; Xu C; Fang T; Zhou D; Xiong X; Wang SY; Xu S; Gao Q
    Mol Cancer Ther; 2023 Apr; 22(4):447-458. PubMed ID: 36780236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
    Johnson N; Li YC; Walton ZE; Cheng KA; Li D; Rodig SJ; Moreau LA; Unitt C; Bronson RT; Thomas HD; Newell DR; D'Andrea AD; Curtin NJ; Wong KK; Shapiro GI
    Nat Med; 2011 Jun; 17(7):875-82. PubMed ID: 21706030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
    Staropoli N; Ciliberto D; Del Giudice T; Iuliano E; Cucè M; Grillone F; Salvino A; Barbieri V; Russo A; Tassone P; Tagliaferri P
    Crit Rev Oncol Hematol; 2018 Nov; 131():83-89. PubMed ID: 30293710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.
    Ning JF; Stanciu M; Humphrey MR; Gorham J; Wakimoto H; Nishihara R; Lees J; Zou L; Martuza RL; Wakimoto H; Rabkin SD
    Nat Commun; 2019 Jul; 10(1):2910. PubMed ID: 31266951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
    Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
    Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 57. PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Al Hadidi S; Aburahma A; Badami S; Upadhaya S
    Oncol Res Treat; 2018; 41(4):226-235. PubMed ID: 29562224
    [No Abstract]   [Full Text] [Related]  

  • 58. PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.
    Mariano G; Ricciardi MR; Trisciuoglio D; Zampieri M; Ciccarone F; Guastafierro T; Calabrese R; Valentini E; Tafuri A; Del Bufalo D; Caiafa P; Reale A
    Oncotarget; 2015 Jun; 6(17):15008-21. PubMed ID: 25938539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
    Choi YE; Meghani K; Brault ME; Leclerc L; He YJ; Day TA; Elias KM; Drapkin R; Weinstock DM; Dao F; Shih KK; Matulonis U; Levine DA; Konstantinopoulos PA; Chowdhury D
    Cell Rep; 2016 Jan; 14(3):429-439. PubMed ID: 26774475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.